|
|
Antiemetic Study Group
Goals, Mission and Annual Meeting Minutes
Chair:
Rebecca A. Clark-Snow, RN, BSN, OCN
Director, Clinical Trials Office
University of Kansas Cancer Center
3901 Rainbow Blvd.
Kansas City, KS 66160
Phone: (913) 588-4714
Fax:(913)588-8766
Email: rclark-snow@kumc.edu
|
Co Chair:
Richard J. Gralla, MD
Vice President, Cancer Services
Chief, Division of Hematology and Oncology
Monter Cancer Center
North Shore-LIJ Health System
450 Lakeville Road
Lake Success, NY 11042
Phone: (516) 734-8992
Fax:(516)734-8991
Email: rgralla@nshs.edu |
Brief Update on MASCC Antiemetic Subcommittee
The antiemetic subcommittee is one of the oldest of the MASCC committees. It was established to deal with the important issue of control of nausea and vomiting induced by chemotherapy and radiotherapy.
During the Congress held in Luxembourg in September 1995 the Subcommittee decided to organize a consensus conference on the use of antiemetics. To identify the most important topics on which consensus should be measured and developed, the Subcommittee elaborated a questionnaire and circulated it to experts. The results of this survey were published (Ballatori E, Roila F, De Angelis V, et al. Clinical and methodological issues in antiemetic therapy: a worldwide survey of experts' opinions. Support Care Cancer 1997; 5: 269-273) and eight major issues were identified that would constitute the basis for the conference. The Consensus Conference was held in Perugia, Italy, 28-29 April 1997 and the papers presented in the eight sessions, corresponding exactly to the issues highlighted by the questionnaire, were published in detail the MASCC Journal (Support Care Cancer 1998; 6: 167-265) and summarized in the ESMO Journal (Ann Oncol 1998; 9: 811-819).
In the following years the Subcommittee has worked in two directions. First, starting from the observation that different recommendations had been made about antiemetic prophylaxis by different published guidelines (ASCO, ESMO, MASCC, NCCN, ASHP, etc), a unified consensus conference was held in New York 19-20 April 2001. The final document of the conference was presented during the ASCO - MASCC Joint Session held in San Francisco May 14, 2001. Second, the members of the Subcommittee have always been most concerned about the evidence that the transferability to clinical practice of results of the antiemetic clinical trials was moderate. To address this problem the Subcommittee planned an international drug utilization study evaluating antiemetic prescriptions and effectiveness against delayed emesis induced by chemotherapy that despite an optimal prophylaxis remains one of the unsolved problems of antiemetic therapy.
|
|
QuickLinks
 Virtual Meeting
Journal Reviews
|
